Note to Affiliate: This document is based on the November 2023 Irish SmPC, the August 2020 J Tube IFU, the March 2019 NJ Tube IFU, the August 2020 PEG IFU, the 2019 CADD Duodopa Patient Information Guide, and the February 2019 CADD Duodopa Pump Operator's Manual.
Duodopa (levodopa/carbidopa intestinal gel) is for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results1
People in this piece are models, not actual patients.
People in this piece are models, not actual patients.
Duodopa (levodopa/carbidopa intestinal gel) is for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results1
People in this piece are models, not actual patients.
Because ON TIME is their time
Duodopa is a device-aided therapy for advanced Parkinson’s disease:
| • | Approximately 4 hours more ‘ON’ time each day – and 4 hours less ‘OFF’ time each day with Duodopa2 |
| • | Increased ‘ON’ time and decreased ‘OFF’ time with Duodopa sustained for more than 4 years3 |
See Duodopa dosing information
| * | PDQ-39 scale assessed several domains including mobility, activities of daily living, and communication. The PDQ-39 Summary Index showed a decrease from baseline of 10.9 points at week 121,2 |
See Duodopa dosing information
| • | Safety profile characterized over 17 years4 |
| • | Approved for use in 48 countries5 |
| • | The most common adverse reaction was complication of device insertion1 |
See Duodopa dosing information
| • | The Duodopa dose is composed of three individually adjusted doses providing continous dopaminergic stimulation for 16 hours.1 Treatment is usually administered during the patient's awake period. If medically justified, Duodopa may be administered for up to 24 hours1 |
| • | After initiation, fine adjustments of these three components of the overall dosage should be made over a few weeks to achieve an optimum dose1 |
See Duodopa dosing information
PATIENT PROFILES
Which of your patients would benefit from Duodopa?
Duodopa is used to treat advanced Parkinson’s disease, which is characterized by severe motor fluctuations and hyperkinesia or dyskinesia that is not well-controlled with oral medications
To ensure that patients receive Duodopa at the appropriate time, clinical criteria to define advanced Parkinson’s disease are required
- A consensus was developed with a panel of 17 movement disorder specialists from 10 countries and proposed 15 indicators of suspected advanced Parkinson’s disease6†
- The consensus group also proposed 7 indicators of when a person may be eligible for device-aided therapy, such as Duodopa6
- Among the 15 indicators, 3 have been proposed as a screening tool – the 5-2-1 criteria:
| – | Taking at least 5 oral levodopa doses per day |
| – | Having at least 2 hours of ‘OFF’ time per waking day |
| – | Having at least 1 hour of troublesome dyskinesia per waking day |
The presence of at least one of these indicators may be a sign of advanced Parkinson’s disease
Is Duodopa right for your advanced Parkinson’s disease patients?
Click on the patient profiles to find out which patient may benefit from Duodopa
PETER
Active with increased bradykinesia
MARIE
Moderately active with unpredictable freezing
GEORGE
Active with troublesome dyskinesia
Peter – active with increased bradykinesia*
| • | Aged 66 years |
| • | Aged 57 years at onset of Parkinson’s disease |
| • | Lives with partner and daughter |
| • | Taking oral levodopa for 6 years but with increasing dyskinesia |
| • | Peter loves his job as a landscape gardener |
Why prescribe Duodopa?
With more than 2 hours a day ‘OFF’ time, Peter’s increased bradykinesia has made him unable to accept new projects, which is affecting his quality of life
*This is a fictional patient but is based on insights from real patients
Marie – moderately active with unpredictable freezing*
| • | Aged 70 years |
| • | Aged 60 years at onset of Parkinson’s disease |
| • | Lives with husband |
| • | Taking oral levodopa for 8 years but with severe motor fluctuations |
| • | A retired journalist, Marie writes for pleasure but poor symptom control has restricted her ability |
Why prescribe Duodopa?
Marie is now taking oral levodopa more than 5 times a day but is still having ‘OFF’ time and unpredictable periods of freezing, both of which are significantly reducing her quality of life
*This is a fictional patient but is based on insights from real patients
George – active with troublesome dyskinesia*
| • | Aged 63 years |
| • | Aged 55 years at onset of Parkinson’s disease |
| • | Lives with wife and two sons |
| • | Taking oral levodopa for 8 years with troublesome dyskinesia |
| • | A highly regarded teacher, George is helping to fund his sons’ education as well as saving for retirement |
Why prescribe Duodopa?
He expressed concern that his oral medication doesn’t seem to be working.
*This is a fictional patient but is based on insights from real patients
Download the Duodopa snapshot brochure
[Placeholder for local DUODOPA indication and abbreviated safety information, as per local requirements]
[Placeholder for local DUODOPA SmPC, as per local requirements]
Please see Duodopa Summary of Product Characteristics for complete prescribing information.
[Please add local Summary of Product Characteristics Information to this link as per local requirements]
I want to receive more information via a product specialist
References
- Duodopa (levodopa/carbidopa intestinal gel) SmPC; [insert current date]
- Olanow CW et al. Lancet Neurol 2014; 13(2):141-149.
- Fernandez HH et al. Mov Disord 2018; 33(6):928-936.
- https://www.ema.europa.eu/en/ medicines/human/orphan-designations/ eu301035. Accessed 9 April 2024.
- Data on File. AbbVie, Inc., ABVRRTI77906.
- Antonini A et al. Curr Med Res Opin 2018; 34(12):2063-2073.
† This study and publication were funded by AbbVie.